A blood-cell marker fell
A small, self-supplementing group had a lower proportion of blood cells with a senescence-associated signal. No placebo group was included. [1]
PLANT FLAVONOIDS · RESEARCH REVIEW
Fisetin.
A closer look at
cellular aging.
A plant compound with intriguing biology and early human signals. Explore the blood-marker findings, the formulation research and the clinical tests that keep healthy-aging expectations grounded.
Explore the findingsIngredient and formulation research. None of the studies below establishes results for a current Neurogan product.
01 / FINDINGS AT A GLANCE
A promising cellular signal.
A clinical story still taking shape.
Fisetin is a plant flavonoid studied for inflammation and cellular senescence. Senescence is a state in which cells stop dividing and can release inflammatory signals. Changing a marker is not the same as making someone younger.
One inflammatory signal
In a small chemotherapy trial, IL-8 changed favorably versus placebo. Other measured markers did not show significant between-group changes. [2]
Benefits are not consistent
A symptom-screening study and a knee trial did not show meaningful treatment advantages. A biological-age pilot was mixed. [4] [5] [6]
02 / A CLOSER LOOK AT THE POSITIVE SIGNAL
What changed in ten people?
This was an observation in people already reporting fisetin use, not a randomized supplement trial. [1]
BLOOD-CELL MARKER · NOT YEARS OF LIFE
−27.2%
Mean relative reduction in the proportion of bright C12FDG-positive peripheral blood mononuclear cells.
Reported SD: 22.203 percentage points of relative change. Paired p=0.0020. n=10. This measures a senescence-associated staining signal in a blood-cell population, not a count of all senescent cells in the body.
The observation window
Before: a baseline blood sample.
Between visits: participants reported 100 mg fisetin daily for a mean of 58 ± 31 days.
Follow-up: the cell-marker proportion and several circulating proteins were lower.
What remains unknown: whether fisetin caused the change, whether senescent cells were actually eliminated, and whether participants gained any health benefit.
Read the subgroup methods and why the finding is preliminary
Six men and four women, mean age 70 ± 13 years, were a selected subgroup of a larger biomarker study. Supplement use was self-reported. Figure 4 reports the cell endpoint in ten people; selected serum analytes used eight to nine samples. There was no randomized comparator and no standardized visit interval.
Natural variation, concurrent changes and selection can affect before-and-after results. The authors also discuss limits of senescence markers. The percentage change is not a demonstrated 27.2% reduction in biological age or in whole-body senescent cells.
03 / HUMAN STUDIES IN DETAIL
The positive and the null findings.
Study sizes, doses and outcomes are kept separate. Expand any study to see what was actually measured.
A first human clue about cellular aging
Several blood signals moved in a favorable direction, but this study cannot establish a treatment effect. [1]
Study details, results & limitations
Population and design: Ten self-supplementing participants from a larger observational cohort, 6 men and 4 women; mean age 70 ± 13 years. No placebo or randomized allocation.
Dose and duration: Self-reported 100 mg/day. Mean time on supplement 58 ± 31 days. Finished-product formulation equivalence was not established.
Results: Mean relative reduction of 27.2% in the C12FDG-bright PBMC proportion, SD 22.203; p=0.0020. MMP-3, MMP-9, IL-6, IL-8 and other serum markers also decreased. These are laboratory endpoints, not function or lifespan.
Limits and applicability: A selected n=10 subgroup cannot establish senolysis in people or predict response to a 500 mg capsule. No verified long-term clinical benefit follows from these biomarker observations.
A small inflammatory-marker trial
IL-8 was the one marker with a significant change relative to placebo. [2]
Study details, results & limitations
Population and design: 37 colorectal cancer patients receiving chemotherapy; double-blind randomized placebo-controlled trial. Fisetin n=18; placebo n=19.
Dose and duration: 100 mg/day for seven consecutive weeks, beginning one week before chemotherapy and continuing through the second cycle.
Results: IL-8, hs-CRP and MMP-7 declined within the fisetin group. Only the IL-8 change differed significantly from placebo (p<0.03). IL-10, hs-CRP, MMP-7 and MMP-9 did not show significant between-group changes.
What was not tested: This was not evidence of tumor shrinkage, improved survival or general healthy-aging benefit. The abstract does not supply reliable group means for a before-and-after chart.
Source access: Primary abstract verified. Detailed outcome tables and adverse-event reporting were not retrieved. Cancer patients should not add supplements without their oncology team.
No clear symptom benefit in Gulf War Illness
Fisetin did not reduce overall symptoms, pain or fatigue convincingly in this small screening study. [4]
Study details, results & limitations
Population and design: Male veterans with Gulf War Illness. The report analyzed 21 men across three separate botanicals; ten contributed to the fisetin primary symptom analysis. This was not a three-ingredient blend.
Dose and duration: One month baseline, then one month placebo, one month 200 mg/day fisetin and one month 800 mg/day. Daily doses were split morning and evening. Participants were blinded; researchers knew phase order but not botanical identity.
Results: Mean severity on a 0–100 scale: baseline 41.9, placebo 41.0, low dose 40.3, high dose 39.5. Overall condition effect p=0.913. Neither pain nor fatigue improved over placebo.
Important details: The final 14 days of each phase were analyzed with mixed models. One participant stopped high-dose fisetin because of nausea and reflux; only earlier phases contributed for that person. Dose and time were confounded by fixed order. Small size, carryover and a nonvalidated single-item scale limit certainty.
Knee pain and cartilage did not improve over placebo
A larger trial tested an intermittent regimen and reported no significant advantage in pain, physical function or cartilage health. [5]
Study details, results & limitations
Population and design: 74 adults with knee osteoarthritis, ages 40–80 eligible; mean age 63 ± 9. Fisetin n=34, placebo n=40. Randomized, double-blind, intention-to-treat analyses.
Dose and duration: Three cycles of 20 mg/kg/day for two consecutive days, followed by 28 days off. Safety was followed for 12 months. Most functional and MRI outcomes were measured at baseline, six and twelve months.
Results: No between-group differences in pain, function, gait or strength. MRI cartilage measurements did not differ significantly between groups or change significantly over time. No significant adverse-event differences (all p>0.5).
Safety and source limits: 185 adverse events across both groups, mostly minor. Four serious events, two per group, were surgeries for apparently unrelated conditions. These are results in a primary conference PDF, not a complete journal article. Sparse dosing under trial oversight is not a self-treatment schedule.
Biological-age testing was not a clear win
Four people had a lower clock estimate, five a higher estimate and one no change. [6]
Study details, results & limitations
Population and design: Ten healthy adults over age 50; uncontrolled pilot. Biological age assessed with a TruAge test.
Dose and duration: 500 mg/day for one week each month, for six months.
Results: 4 of 10 had a reduced biological-age estimate; 5 of 10 increased; 1 of 10 unchanged. Telomere length did not change significantly. No adverse effects were noted in the abstract.
Interpretation: Clock variability and the absence of placebo make causal conclusions impossible. This is not proof that fisetin slows or accelerates aging. The study does not support an anti-aging recommendation.
Source access: Primary abstract only. No invented individual clock values or efficacy curve is presented.
04 / FORMULATION & ABSORPTION
Delivery can change blood exposure.
A specific micelle-in-hydrogel formulation called FF-20 increased measured fisetin exposure. This is a formulation result, not a clinical benefit or a general result for liposomal capsules. [3]
Dose-normalized fisetin exposure over 12 hours
AUC₀–₁₂, ng·h/mL, normalized to account for unequal active doses
0250500
Dose reconciliation, blood sampling and conflicts of interest
Fifteen healthy adults (12 men, 3 women; ages 22–55) received 1,000 mg of each preparation on separate occasions, with a ten-day washout. FF-20 supplied 192 mg actual fisetin; the unformulated preparation supplied 982 mg. The paper explicitly adjusted its published values for this active-content difference.
Blood samples were taken before dosing and at 0.5, 1, 2, 3, 5, 8 and 12 hours. Table 1 reports a 26.9-fold normalized AUC difference. It does not establish 26.9-fold better health effects or equivalence to any Neurogan liposomal product.
The assay measured free fisetin and geraldol, not all conjugated metabolites. The manufacturer funded the study and owns the proprietary technology. Although the abstract says no adverse events, the full text notes bloating and reduced appetite reported under both preparations.
05 / THE LONGEVITY QUESTION
Mice provide a reason to study.
Not a promise for people.
The landmark 2018 paper combined cell, mouse and excised-human-tissue experiments. Only the mice underwent a lifespan experiment. [7]
01
Cells
Screen flavonoids for senescence-associated signals.
02
Older mice
Test tissue markers, pathology and survival.
03
Human research
Ask whether marker changes lead to better health.
2018 primary study: distinct experiments, distinct doses
Acute mouse experiment: 22–24-month-old wild-type mice received 100 mg/kg by oral gavage for five days. Senescence-associated signals fell in some cell populations, not every cell type.
Lifespan experiment: a separate mouse group received a diet containing 500 ppm fisetin starting at 85 weeks of age. Median and maximum lifespan were extended versus control diet. This is a dietary concentration in mice, not a human capsule dose.
Human tissue: surgically removed fat tissue from three female donors was studied outside the body. Tissue findings do not mean volunteers swallowed fisetin or experienced senescent-cell clearance.
No human lifespan percentage is inferred from these experiments. The 2024 review identifies major gaps in dose, pharmacokinetics, safety and clinical endpoints. [8]
Registered studies and published protocols are not positive results
NCT06133634 is investigating vascular function in older adults. The live registry record was active, not recruiting, with no posted results at review; its latest posted update was November 12, 2025. [9]
A 2026 triple-blind trial protocol describes 100 mg/day for seven weeks in adults aged at least 50, with plasma suPAR change as the primary endpoint. It is a plan for evaluating inflammation and safety, not a report that the intervention worked. [10]
06 / FROM RESEARCH TO PRODUCT
Same ingredient.
Different evidence.
Product records and label images were checked September 10, 2026. Listed amounts are not independent potency tests, and more milligrams do not establish more benefit.
Fisetin Capsules
500 mg
Listed per one capsule; 30 capsules per bottle. Description identifies Rhus succedanea fruit extract. Suggested use: one capsule daily with food.
The daily serving is higher than the 100 mg/day inflammatory-marker trial and observational subgroup. The 500 mg biological-age pilot used an intermittent schedule and had mixed results.
Liposomal Fisetin
1,000 mg complex
Label: two-capsule serving; 60 capsules per bottle. Fisetin/phospholipid complex from sunflower. Directions list one to two capsules daily.
The label does not separately quantify active fisetin within the complex. This is not confirmed as FF-20 and does not inherit its dose-normalized absorption result.
Clinical senolytic activity, longer life and finished-product efficacy have not been established by these product records. The liposomal listing’s delivery language is not a head-to-head human pharmacokinetic test.
07 / SAFETY & OPEN QUESTIONS
Small studies cannot settle long-term safety.
Use study doses to understand research, not as instructions for a personal regimen.
What has been observed?
Digestive complaints, fatigue and other mild-to-moderate events occurred in the Gulf War screening study. One person stopped the high-dose phase because of worsening nausea and reflux. The knee report found no adverse-event excess, but it does not establish safety for daily high doses over years. [4] [5]
Who should get advice first?
Talk with a clinician or pharmacist if you take prescription medicines, are receiving cancer treatment, have liver or kidney disease, or are considering intermittent high-dose use. Drug-interaction risks are incompletely characterized. Pregnancy, breastfeeding and pediatric safety are not established in these studies.
Bottom line: Fisetin has credible biological activity and a small human biomarker signal worth following. Longer life, reliable age reversal and clinically useful senescent-cell clearance in people remain unproven.
SOURCES & FURTHER READING
Read what each finding rests on.
Focused evidence review, not an exhaustive systematic review. Primary full text, abstracts, conference reports and registrations are labeled separately. Research and product records checked September 10, 2026.
- PRIMARY FULL TEXT · OBSERVATIONAL
Hambright et al. · Clinical validation of C12FDG
Aging Cell, 2024. DOI: 10.1111/acel.14113. The self-supplementing subgroup is n=10, not the full biomarker-validation cohort. Figure 4 and its caption supply the dose, timing and marker change.
Read source 1 ↗ - PRIMARY ABSTRACT · RANDOMIZED TRIAL
Farsad-Naeimi et al. · Inflammation during chemotherapy
Food & Function, 2018. PMID 29541713; DOI: 10.1039/c7fo01898c. Abstract verified. Full outcome tables were not retrieved. Only IL-8 change differed significantly from placebo.
Read source 2 ↗ - PRIMARY FULL TEXT · PHARMACOKINETICS
Krishnakumar et al. · FF-20 formulation
Journal of Nutritional Science, 2022. PMID 36304817; DOI: 10.1017/jns.2022.72. Table 1 explicitly normalizes values for unequal active fisetin intake. Manufacturer-funded; proprietary technology.
Read source 3 ↗ - PRIMARY FULL TEXT · CONTROLLED SCREENING
Hodgin et al. · Gulf War Illness
International Journal of Environmental Research and Public Health, 2021. PMID 33802381. Methods, results section 3.4 and Figure 3 provide fisetin-specific primary outcome data. The botanicals were tested serially, not as a blend.
Read source 4 ↗ - PRIMARY CONFERENCE REPORT · RANDOMIZED TRIAL
Tashman et al. · Knee osteoarthritis
ORS 2025 Annual Meeting, paper 429. Full one-page primary conference PDF retrieved. This is not a full journal trial article. Related OARSI abstract DOI: 10.1016/j.joca.2025.02.667 is not counted as another trial.
Read source 5 ↗ - PRIMARY ABSTRACT · UNCONTROLLED PILOT
Lee & Burns · Biological-age testing
Alternative Therapies in Health and Medicine, 2024. PMID 39269340. Abstract verified; detailed individual data and full methods not retrieved. Ten adults, mixed clock results, no significant telomere change.
Read source 6 ↗ - PRIMARY FULL TEXT · MICE & TISSUE
Yousefzadeh et al. · Senescence and lifespan
EBioMedicine, 2018. PMID 30279143; DOI: 10.1016/j.ebiom.2018.09.015. Figures 4 and 5 separate acute mouse/tissue experiments from the long-term mouse lifespan experiment.
Read source 7 ↗ - REVIEW · ABSTRACT VERIFIED
Tavenier et al. · Fisetin as a senotherapeutic agent
Mechanisms of Ageing and Development, 2024. PMID 39384074; DOI: 10.1016/j.mad.2024.111995. Useful synthesis of preclinical work, human studies and unresolved safety, dose and endpoint questions. Not another clinical trial.
Read source 8 ↗ - REGISTRY · NO POSTED RESULTS
Fisetin to Improve Vascular Function in Older Adults
NCT06133634. Live registry API checked September 10, 2026: active, not recruiting; hasResults=false. Last posted update November 12, 2025. Dates and status are registry reports, not proof of benefit.
Read source 9 ↗ - PUBLISHED PROTOCOL · NOT RESULTS
Low-dose fisetin and chronic inflammation
Tavenier et al., 2026. PMID 42633989; DOI: 10.1111/bcpt.70290. Triple-blind trial protocol: 100 mg daily for 7 weeks in adults aged 50 or older. Primary endpoint is change in suPAR.
Read source 10 ↗